Auransa Enters into Exclusive Licensing Agreement with China Oncology Focus Limited, an Affiliate of Lee’s Pharmaceutical Holdings, for Rights to AU018 in Greater China and Southeast Asia 2018.12.20

 
PALO ALTO, CA, AND HONG KONG – December 19, 2018 – Auransa, Inc., an artificial intelligence (AI)-driven pharmaceutical company developing precision medicines in areas of significant unmet medical need, and China Oncology Focus Limited (“COF”), an affiliate of Lee’s Pharmaceutical Holdings Ltd. (“Lee’s Pharma”), today announced that the companies have entered into a licensing agreement granting COF exclusive rights to develop and commercialize AU018 in China and other countries of Southeast Asia. Under terms of the agreement, Auransa will receive an upfront payment, potential future milestone payments and high single digit royalties on future net sales. In total, Auransa is eligible to receive up to $22.5 million upon successful attainment of key milestones.
 
  Download  


© Lee's Pharmaceutical Holdings Limited     Terms of Use   |   Privacy Statement Designed by YSD